Patents by Inventor Paul F. Lambert
Paul F. Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11058699Abstract: A method of inhibiting double-stranded DNA virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors. In another embodiment, the method involves administering an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors to a susceptible tissue or cell.Type: GrantFiled: June 29, 2009Date of Patent: July 13, 2021Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Paul F. Lambert, Shane Pearce, Paul G. Ahlquist, Dohun Pyeon
-
Patent number: 9949980Abstract: A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.Type: GrantFiled: June 2, 2015Date of Patent: April 24, 2018Assignee: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, Paul G. Ahlquist, Dohun Pyeon, Hao Shun Huang
-
Patent number: 9889101Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.Type: GrantFiled: March 12, 2012Date of Patent: February 13, 2018Assignee: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, SangHyuk Chung
-
Patent number: 9790553Abstract: Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.Type: GrantFiled: July 29, 2011Date of Patent: October 17, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Dohun Pyeon, Paul F. Lambert, Michael A. Newton, Paul G. Ahlquist
-
Publication number: 20150297602Abstract: A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.Type: ApplicationFiled: June 2, 2015Publication date: October 22, 2015Inventors: Paul F. Lambert, Paul G. Ahlquist, Dohun Pyeon, Hao Shun Huang
-
Patent number: 9066951Abstract: A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.Type: GrantFiled: May 29, 2009Date of Patent: June 30, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, Paul G. Ahlquist, Dohun Pyeon, Hao Shun Huang
-
Publication number: 20120171306Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.Type: ApplicationFiled: March 12, 2012Publication date: July 5, 2012Applicant: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, SangHyuk Chung
-
Patent number: 8158614Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.Type: GrantFiled: January 26, 2010Date of Patent: April 17, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, SangHyuk Chung
-
Publication number: 20110301059Abstract: Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.Type: ApplicationFiled: July 29, 2011Publication date: December 8, 2011Inventors: DOHUN PYEON, PAUL F. LAMBERT, MICHAEL A. NEWTON, PAUL G. AHLQUIST
-
Patent number: 8012678Abstract: Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.Type: GrantFiled: July 24, 2008Date of Patent: September 6, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Dohun Pyeon, Paul F. Lambert, Michael A. Newton, Paul G. Ahlquist
-
Publication number: 20110189258Abstract: A method of inhibiting double-stranded DNA virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors. In another embodiment, the method involves administering an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors to a susceptible tissue or cell.Type: ApplicationFiled: June 29, 2009Publication date: August 4, 2011Inventors: Dohun Pyeon, Paul F. Lambert, Shane Pearce, Paul G. Ahlquist
-
Publication number: 20110165220Abstract: A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.Type: ApplicationFiled: May 29, 2009Publication date: July 7, 2011Inventors: Paul F. Lambert, Paul G. Ahlquist, Dohun Pyeon, Hao Shun Huang
-
Publication number: 20100203164Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.Type: ApplicationFiled: January 26, 2010Publication date: August 12, 2010Applicant: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, SangHyuk Chung
-
Patent number: 7563597Abstract: A method of producing a packaged DNA sequence is disclosed. In one embodiment, the method comprises the steps of: (a) selecting a DNA sequence to be packaged and a papillomaviral capsid sequence, wherein the DNA sequence to be packaged is between 7 Kb-8.5 Kb, (b) co-transfecting the products of step (a) into transfectable cells, wherein the DNA sequence is packaged, and (c) purifying packaged particles.Type: GrantFiled: January 30, 2006Date of Patent: July 21, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Paul G. Ahlquist, Dohun Pyeon, Paul F. Lambert
-
Publication number: 20090148950Abstract: A method of producing a packaged DNA sequence is disclosed. In one embodiment, the method comprises the steps of: (a) selecting a DNA sequence to be packaged and a papillomaviral capsid sequence, wherein the DNA sequence to be packaged is between 7 Kb-8.5 Kb, (b) co-transfecting the products of step (a) into transfectable cells, wherein the DNA sequence is packaged, and (c) purifying packaged particles.Type: ApplicationFiled: January 30, 2006Publication date: June 11, 2009Inventors: Paul G. Ahlquist, Dohun Pyeon, Paul F. Lambert
-
Publication number: 20090136486Abstract: Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.Type: ApplicationFiled: July 24, 2008Publication date: May 28, 2009Inventors: Dohun Pyeon, Paul F. Lambert, Michael A. Newton, Paul G. Ahlquist